1 min read
Add as a preferred source on GoogleScinai Immunotherapeutics Enters Financing Agreements for About $4 Million
The agreements cover 2.46 million American depositary shares or pre-funded warrants, plus warrants for up to 3.69 million additional shares.
Scinai Immunotherapeutics (SCNI) entered financing agreements for approximately $4 million in gross proceeds, combining American depositary shares or pre-funded warrants with warrants for additional shares.
The agreements cover 2.46 million American depositary shares (ADSs) or pre-funded warrants. Series A-1 warrants give holders the right to purchase up to 3.69 million more ADSs.
The agreements were announced Oct. 14, 2026.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.